资本动态│雅培通过并购Topera进入电生理领域

2014-10-30

据10月29日雅培官方网站显示,雅培以2.5亿美元的首付款和未来潜在的收益付款与风险投资企业Topera医疗器械公司达成并购协议。通过此次并购,雅培将获得Topera的转子识别系统,并将在电生理领域开拓一片天地。据悉,全球电生理市场价值约30亿美元,且每年以两位数的速率增长。在电生理领域,已经有强生、圣犹达、美敦力、波士顿科学四大生产厂家。Topera的平台包括专有的FIRMap诊断导管和RhythmView工作站中的软件标测技术。其中,FIRMap诊断导管已于2013年末在美国和欧洲上市;第三代Topera3D标测系统的导管、软件和工作站于2014年1月获得FDA的510(k)认证。


Topera的平台可用于结合现在的导管消融治疗。在一家独立的、多中心的、医生发起的包含较难治疗的疾病的试验中,结合Topera转子识别系统,采用导管消融治疗复杂房颤时,(治疗)可获得较高的成功率。Topera转子识别系统成功率达87.5%,在对患者实施第一次消融后。一年后进行随访,仍有80.5%的成功率,而仅仅采用现存导管消融法治疗的患者一年后成功率仅为50-60%(根据Journalof American College of Cardiology在2012年发表的CONFIRM试验)。在治疗房颤的过程中,Topera的技术以最少的程序和更少的消融时间提高长期的治疗效果。使用Topera的技术,医生能够准确消融引起心律不齐的心脏内的病灶(即转子)。在美国、欧洲和日本的主要房颤市场上,导管消融依旧是最广泛的治疗方法。


此外,雅培通过获得AdvancedCardiac Therapeutics (ACT)的购买权,进一步巩固了其在电生理市场的地位。ACT是一家立足于开发消融导管技术以提高消融过程的安全性和有效性的医疗器械公司。一旦被商业化,ACT的消融技术可以应用于Topera的3D标测系统。

Abbott announced this morning that itisacquiring a private venture-backed medical device company Topera for$250Mupfront and future potential milestone payments. With the acquisitionofTopera, ABT is attempting to carve out a niche in the highly competitive$3Bglobal electrophysiology market where there are already 4 major players(JNJ,STJ, MDT, BSX) by gaining access to Topera's rotor identificationsystem.Topera's platform includes a proprietary diagnostic catheter FIRMapandsoftware mapping technology within the RhythmView workstation. TheFIRMappanoramic contact-mapping basket catheter received regulatory approvaland waslaunched by Topera in the U.S. and Europe in late 2013. The catheter,software,and workstation received 510k approval in January, 2014 as the thirdgenerationTopera 3D mapping system.

Topera's platform is used inconjunctionwith current catheter ablation therapies. Topera's rotor identificationsystemwhen used with catheter ablation for the treatment of afib hasdemonstratedlong-term success rates in an independent, multi-center, physiciansponsoredtrial which included cases that were difficult to treat. Topera'srotoridentification system achieved an 87.5% success rate in patientsundergoing afirst ablation procedure and an 80.5% success rate at one-yearfollow up vs.50-60% success rates achieved for patients treated with existingcatheterablation therapy alone (the CONFIRM Trial published in the Journal ofAmericanCollege of Cardiology 2012). Topera's technology has the potential toimprovelong-term outcomes with fewer procedures and achieve shorter ablationtimes forafib procedures given the technology's ability to hone in on the problematicregionsof the heart that are associated with causing irregular heartbeats('rotors').Catheter ablation remains an underpenetrated treatment for afib inthe majormarkets of the U.S., EU, and Japan.

Abbott is also positioning itself tofurtherbuild out its market opportunity in the EP space by securing the rightstoacquire Advanced Cardiac Therapeutics (ACT), a private venture-backedmedicaldevice company developing an ablation catheter technology designed toimprovethe safety and effectiveness of ablation procedures. The ACTablationtechnology once commercialized will be complementary to the Topera 3Dmappingsystem.

Topera医疗器械公司是一家立足于研发创新型电生理技术以提高房颤疾病的诊断和治疗水平的公司。Topera公司已经研发出新型导管和标测系统,即转子识别系统,它可以帮助医生更好地发现心脏中引发房颤的病灶区域。

【文章来源】雅培官网和COWEN的相关资料。



微信号:CHC医疗传媒

本站点由 非是非 制作和维护。